{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T05:47:35Z","timestamp":1794030455484,"version":"4.8.0"},"reference-count":249,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T00:00:00Z","timestamp":1755907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T00:00:00Z","timestamp":1755907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["IRG-21-133-64-02"],"award-info":[{"award-number":["IRG-21-133-64-02"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002590","name":"American Lung Association","doi-asserted-by":"publisher","award":["Lung Cancer Discovery Award"],"award-info":[{"award-number":["Lung Cancer Discovery Award"]}],"id":[{"id":"10.13039\/100002590","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007038","name":"Lung Cancer Research Foundation","doi-asserted-by":"publisher","award":["Daiichi Sankyo \u2013 AstraZeneca Research Grant on Antibody Drug Conjugates"],"award-info":[{"award-number":["Daiichi Sankyo \u2013 AstraZeneca Research Grant on Antibody Drug Conjugates"]}],"id":[{"id":"10.13039\/100007038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007849","name":"Respiratory Health Association","doi-asserted-by":"publisher","award":["2025 Lung Cancer Research Award"],"award-info":[{"award-number":["2025 Lung Cancer Research Award"]}],"id":[{"id":"10.13039\/100007849","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Natural killer (NK) cells are a crucial part of the innate immune system and serve as an important effector for killing tumor cells through direct cytolytic activity or immunomodulatory signaling to T cells and antigen presenting cells. NK cells are correlated with increased tumor control and better overall patient survival across various types of cancers including non-small cell lung cancer (NSCLC). Despite their promising potential for anti-tumor killing, NK cell function is often diminished within the tumor microenvironment. There are many factors that lead to decreased tumor-infiltrating NK cell killing, including immunoinhibitory factors from tumor cells and resident tissues, acquired immune tolerance, NK cell exhaustion, and the hypoxic state of the tumor microenvironment. Unleashing NK cell activity therefore has high potential to create a new class of immunotherapy that could combat both primary and acquired resistance to current checkpoint inhibitors. In this review we discuss mechanistic details of NK cell tumor killing, NK cell immunosuppression, and gaps in knowledge regarding highly complex microenvironment-specific effects on NK cell function. We also discuss the promise and limitations of emerging NK-cell based therapeutic strategies.<\/jats:p>","DOI":"10.1186\/s13046-025-03503-7","type":"journal-article","created":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T03:22:06Z","timestamp":1755919326000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Unleashing NK cells for cancer immunotherapy in lung cancer: biologic challenges and clinical advances"],"prefix":"10.1186","volume":"44","author":[{"given":"Quinlan","family":"McLaughlin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothy K.","family":"Sojka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sytse J.","family":"Piersma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Sethakorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,23]]},"reference":[{"key":"3503_CR1","doi-asserted-by":"publisher","first-page":"102545","DOI":"10.1016\/j.ctrv.2023.102545","volume":"116","author":"A Desai","year":"2023","unstructured":"Desai A, Peters S. Immunotherapy-based combinations in metastatic NSCLC. Cancer Treat Rev. 2023;116:102545.","journal-title":"Cancer Treat Rev"},{"issue":"8","key":"3503_CR2","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1093\/annonc\/mdz167","volume":"30","author":"J Mazieres","year":"2019","unstructured":"Mazieres J, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol. 2019;30(8):1321\u20138.","journal-title":"Ann Oncol"},{"issue":"1","key":"3503_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13045-020-01014-w","volume":"14","author":"S Liu","year":"2021","unstructured":"Liu S, et al. NK cell-based cancer immunotherapy: from basic biology to clinical development. J Hematol Oncol. 2021;14(1):7.","journal-title":"J Hematol Oncol"},{"issue":"5","key":"3503_CR4","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/ni1582","volume":"9","author":"E Vivier","year":"2008","unstructured":"Vivier E, et al. Functions of natural killer cells. Nat Immunol. 2008;9(5):503\u201310.","journal-title":"Nat Immunol"},{"key":"3503_CR5","doi-asserted-by":"crossref","unstructured":"Hashemi E, Malarkannan S. Tissue-Resident NK cells: development, maturation, and clinical relevance. Cancers (Basel), 2020;12(6).","DOI":"10.3390\/cancers12061553"},{"issue":"4","key":"3503_CR6","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/j.1365-2567.2008.03027.x","volume":"126","author":"A Poli","year":"2009","unstructured":"Poli A, et al. CD56bright natural killer (NK) cells: an important NK cell subset. Immunology. 2009;126(4):458\u201365.","journal-title":"Immunology"},{"issue":"6","key":"3503_CR7","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.21037\/tlcr-20-765","volume":"10","author":"JB Hess","year":"2021","unstructured":"Hess JB, Sutherland KD, Best SA. Exploring natural killer cell immunology as a therapeutic strategy in lung cancer. Transl Lung Cancer Res. 2021;10(6):2788\u2013805.","journal-title":"Transl Lung Cancer Res"},{"issue":"8","key":"3503_CR8","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1038\/s41590-024-01883-0","volume":"25","author":"L Rebuffet","year":"2024","unstructured":"Rebuffet L, et al. High-dimensional single-cell analysis of human natural killer cell heterogeneity. Nat Immunol. 2024;25(8):1474\u201388.","journal-title":"Nat Immunol"},{"issue":"36","key":"3503_CR9","doi-asserted-by":"publisher","first-page":"14725","DOI":"10.1073\/pnas.1110900108","volume":"108","author":"S Lopez-Verges","year":"2011","unstructured":"Lopez-Verges S, et al. Expansion of a unique CD57(+)NKG2Chi natural killer cell subset during acute human cytomegalovirus infection. Proc Natl Acad Sci U S A. 2011;108(36):14725\u201332.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"3503_CR10","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.1182\/blood-2002-09-2876","volume":"101","author":"TA Fehniger","year":"2003","unstructured":"Fehniger TA, et al. CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood. 2003;101(8):3052\u20137.","journal-title":"Blood"},{"key":"3503_CR11","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.3389\/fimmu.2019.01416","volume":"10","author":"J Cong","year":"2019","unstructured":"Cong J, Wei H. Natural killer cells in the lungs. Front Immunol. 2019;10:1416.","journal-title":"Front Immunol"},{"issue":"12","key":"3503_CR12","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1002\/eji.202149608","volume":"52","author":"X Chen","year":"2022","unstructured":"Chen X, et al. Tissue-resident CD69(+) CXCR6(+) natural killer cells with exhausted phenotype accumulate in human non-small cell lung cancer. Eur J Immunol. 2022;52(12):1993\u20132005.","journal-title":"Eur J Immunol"},{"issue":"5","key":"3503_CR13","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.it.2007.03.005","volume":"28","author":"J Hanna","year":"2007","unstructured":"Hanna J, Mandelboim O. When killers become helpers. Trends Immunol. 2007;28(5):201\u20136.","journal-title":"Trends Immunol"},{"issue":"1","key":"3503_CR14","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12943-020-01238-x","volume":"19","author":"SY Wu","year":"2020","unstructured":"Wu SY, et al. Natural killer cells in cancer biology and therapy. Mol Cancer. 2020;19(1):120.","journal-title":"Mol Cancer"},{"issue":"2","key":"3503_CR15","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/JLB.3RU0420-668RR","volume":"109","author":"SA Erokhina","year":"2021","unstructured":"Erokhina SA, et al. HLA-DR-expressing NK cells: effective killers suspected for antigen presentation. J Leukoc Biol. 2021;109(2):327\u201337.","journal-title":"J Leukoc Biol"},{"issue":"7","key":"3503_CR16","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1084\/jem.20050128","volume":"202","author":"RB Mailliard","year":"2005","unstructured":"Mailliard RB, et al. IL-18-induced CD83\u2009+\u2009CCR7\u2009+\u2009NK helper cells. J Exp Med. 2005;202(7):941\u201353.","journal-title":"J Exp Med"},{"issue":"3","key":"3503_CR17","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1097\/CJI.0b013e31820b370b","volume":"34","author":"JL Wong","year":"2011","unstructured":"Wong JL, et al. Helper activity of natural killer cells during the dendritic cell-mediated induction of melanoma-specific cytotoxic T cells. J Immunother. 2011;34(3):270\u20138.","journal-title":"J Immunother"},{"issue":"3","key":"3503_CR18","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1084\/jem.20010938","volume":"195","author":"F Gerosa","year":"2002","unstructured":"Gerosa F, et al. Reciprocal activating interaction between natural killer cells and dendritic cells. J Exp Med. 2002;195(3):327\u201333.","journal-title":"J Exp Med"},{"issue":"9\u201310","key":"3503_CR19","doi-asserted-by":"publisher","first-page":"352","DOI":"10.2119\/molmed.2009.00035","volume":"15","author":"A Lunemann","year":"2009","unstructured":"Lunemann A, Lunemann JD, Munz C. Regulatory NK-cell functions in inflammation and autoimmunity. Mol Med. 2009;15(9\u201310):352\u20138.","journal-title":"Mol Med"},{"issue":"1","key":"3503_CR20","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/JLB.3MR0820-685R","volume":"109","author":"NW Zwirner","year":"2021","unstructured":"Zwirner NW, Domaica CI, Fuertes MB. Regulatory functions of NK cells during infections and cancer. J Leukoc Biol. 2021;109(1):185\u201394.","journal-title":"J Leukoc Biol"},{"issue":"3","key":"3503_CR21","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1084\/jem.20011149","volume":"195","author":"G Ferlazzo","year":"2002","unstructured":"Ferlazzo G, et al. Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J Exp Med. 2002;195(3):343\u201351.","journal-title":"J Exp Med"},{"issue":"5","key":"3503_CR22","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.4049\/jimmunol.0801124","volume":"182","author":"AW Mailloux","year":"2009","unstructured":"Mailloux AW, Young MR. NK-dependent increases in CCL22 secretion selectively recruits regulatory T cells to the tumor microenvironment. J Immunol. 2009;182(5):2753\u201365.","journal-title":"J Immunol"},{"issue":"2","key":"3503_CR23","doi-asserted-by":"publisher","first-page":"e1527498","DOI":"10.1080\/2162402X.2018.1527498","volume":"8","author":"E Picard","year":"2019","unstructured":"Picard E, et al. Circulating NKp46(+) natural killer cells have a potential regulatory property and predict distinct survival in Non-Small cell lung cancer. Oncoimmunology. 2019;8(2):e1527498.","journal-title":"Oncoimmunology"},{"key":"3503_CR24","first-page":"8","volume":"13","author":"P Spear","year":"2013","unstructured":"Spear P, et al. NKG2D ligands as therapeutic targets. Cancer Immun. 2013;13:8.","journal-title":"Cancer Immun"},{"issue":"6","key":"3503_CR25","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1158\/2326-6066.CIR-15-0098","volume":"3","author":"LL Lanier","year":"2015","unstructured":"Lanier LL. NKG2D receptor and its ligands in host defense. Cancer Immunol Res. 2015;3(6):575\u201382.","journal-title":"Cancer Immunol Res"},{"issue":"7","key":"3503_CR26","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1093\/intimm\/dxn038","volume":"20","author":"M Le Chansac","year":"2008","unstructured":"Le Chansac M. Potentiation of NK cell-mediated cytotoxicity in human lung adenocarcinoma: role of NKG2D-dependent pathway. Int Immunol. 2008;20(7):801\u201310.","journal-title":"Int Immunol"},{"key":"3503_CR27","doi-asserted-by":"crossref","unstructured":"Li Y et al. Unlocking the therapeutic potential of the NKG2A-HLA-E immune checkpoint pathway in T cells and NK cells for cancer immunotherapy. J Immunother Cancer, 2024;12(10).","DOI":"10.1136\/jitc-2024-009934"},{"issue":"1","key":"3503_CR28","doi-asserted-by":"publisher","first-page":"10555","DOI":"10.1038\/s41598-023-37779-6","volume":"13","author":"M Kaulfuss","year":"2023","unstructured":"Kaulfuss M, et al. The NK cell checkpoint NKG2A maintains expansion capacity of human NK cells. Sci Rep. 2023;13(1):10555.","journal-title":"Sci Rep"},{"issue":"1","key":"3503_CR29","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/s40425-019-0761-3","volume":"7","author":"T van Hall","year":"2019","unstructured":"van Hall T, et al. Monalizumab: inhibiting the novel immune checkpoint NKG2A. J Immunother Cancer. 2019;7(1):263.","journal-title":"J Immunother Cancer"},{"key":"3503_CR30","doi-asserted-by":"crossref","unstructured":"De Louche CD, Roghanian A. Human inhibitory leukocyte Ig-like receptors: from immunotolerance to immunotherapy. JCI Insight, 2022;7(2).","DOI":"10.1172\/jci.insight.151553"},{"key":"3503_CR31","doi-asserted-by":"crossref","unstructured":"Chen H et al. Antagonistic anti-LILRB1 monoclonal antibody regulates antitumor functions of natural killer cells. J Immunother Cancer, 2020;8(2).","DOI":"10.1136\/jitc-2019-000515"},{"issue":"3","key":"3503_CR32","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1096\/fj.09-135194","volume":"24","author":"B Favier","year":"2010","unstructured":"Favier B, et al. ILT2\/HLA-G interaction impairs NK-cell functions through the Inhibition of the late but not the early events of the NK-cell activating synapse. FASEB J. 2010;24(3):689\u201399.","journal-title":"FASEB J"},{"issue":"6055","key":"3503_CR33","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/319675a0","volume":"319","author":"K Karre","year":"1986","unstructured":"Karre K, et al. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature. 1986;319(6055):675\u20138.","journal-title":"Nature"},{"issue":"12","key":"3503_CR34","doi-asserted-by":"publisher","first-page":"4539","DOI":"10.4049\/jimmunol.138.12.4539","volume":"138","author":"WE Seaman","year":"1987","unstructured":"Seaman WE, et al. Depletion of natural killer cells in mice by monoclonal antibody to NK-1.1. Reduction in host defense against malignancy without loss of cellular or humoral immunity. J Immunol. 1987;138(12):4539\u201344.","journal-title":"J Immunol"},{"issue":"4","key":"3503_CR35","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1093\/intimm\/13.4.459","volume":"13","author":"MJ Smyth","year":"2001","unstructured":"Smyth MJ, Crowe NY, Godfrey DI. NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int Immunol. 2001;13(4):459\u201363.","journal-title":"Int Immunol"},{"issue":"12","key":"3503_CR36","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1158\/2326-6066.CIR-18-0062","volume":"6","author":"F Concha-Benavente","year":"2018","unstructured":"Concha-Benavente F, et al. PD-L1 mediates dysfunction in activated PD-1(+) NK cells in head and neck cancer patients. Cancer Immunol Res. 2018;6(12):1548\u201360.","journal-title":"Cancer Immunol Res"},{"issue":"7","key":"3503_CR37","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1158\/2326-6066.CIR-18-0500","volume":"7","author":"J Cursons","year":"2019","unstructured":"Cursons J, et al. A gene signature predicting natural killer cell infiltration and improved survival in melanoma patients. Cancer Immunol Res. 2019;7(7):1162\u201374.","journal-title":"Cancer Immunol Res"},{"key":"3503_CR38","doi-asserted-by":"crossref","unstructured":"Li B et al. Natural killer cell and stroma abundance are independently prognostic and predict gastric cancer chemotherapy benefit. JCI Insight, 2020;5(9).","DOI":"10.1172\/jci.insight.136570"},{"key":"3503_CR39","doi-asserted-by":"publisher","first-page":"850745","DOI":"10.3389\/fimmu.2022.850745","volume":"13","author":"P Song","year":"2022","unstructured":"Song P, et al. Identification and validation of a novel signature based on NK cell marker genes to predict prognosis and immunotherapy response in lung adenocarcinoma by integrated analysis of Single-Cell and bulk RNA-Sequencing. Front Immunol. 2022;13:850745.","journal-title":"Front Immunol"},{"issue":"5","key":"3503_CR40","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1002\/1878-0261.13597","volume":"18","author":"L Kuncman","year":"2024","unstructured":"Kuncman L, et al. High FLT3 expression increases immune-cell infiltration in the tumor microenvironment and correlates with prolonged disease-free survival in patients with non-small cell lung cancer. Mol Oncol. 2024;18(5):1316\u201326.","journal-title":"Mol Oncol"},{"issue":"5","key":"3503_CR41","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.cell.2018.01.004","volume":"172","author":"JP Bottcher","year":"2018","unstructured":"Bottcher JP, et al. NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control. Cell. 2018;172(5):1022\u2013e103714.","journal-title":"Cell"},{"issue":"6421","key":"3503_CR42","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1126\/science.aas9090","volume":"362","author":"M Ruscetti","year":"2018","unstructured":"Ruscetti M, et al. NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination. Science. 2018;362(6421):1416\u201322.","journal-title":"Science"},{"issue":"8","key":"3503_CR43","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41568-020-0272-z","volume":"20","author":"ND Huntington","year":"2020","unstructured":"Huntington ND, Cursons J, Rautela J. The cancer-natural killer cell immunity cycle. Nat Rev Cancer. 2020;20(8):437\u201354.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"3503_CR44","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S0169-5002(01)00292-6","volume":"35","author":"FR Villegas","year":"2002","unstructured":"Villegas FR, et al. Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. Lung Cancer. 2002;35(1):23\u20138.","journal-title":"Lung Cancer"},{"key":"3503_CR45","doi-asserted-by":"publisher","first-page":"3101","DOI":"10.3389\/fimmu.2018.03101","volume":"9","author":"B Stankovic","year":"2018","unstructured":"Stankovic B, et al. Immune cell composition in human Non-small cell lung cancer. Front Immunol. 2018;9:3101.","journal-title":"Front Immunol"},{"issue":"1","key":"3503_CR46","doi-asserted-by":"publisher","first-page":"2233402","DOI":"10.1080\/2162402X.2023.2233402","volume":"12","author":"D Brownlie","year":"2023","unstructured":"Brownlie D, et al. Accumulation of tissue-resident natural killer cells, innate lymphoid cells, and CD8(+) T cells towards the center of human lung tumors. Oncoimmunology. 2023;12(1):2233402.","journal-title":"Oncoimmunology"},{"issue":"16","key":"3503_CR47","doi-asserted-by":"publisher","first-page":"5412","DOI":"10.1158\/0008-5472.CAN-10-4179","volume":"71","author":"S Platonova","year":"2011","unstructured":"Platonova S, et al. Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. Cancer Res. 2011;71(16):5412\u201322.","journal-title":"Cancer Res"},{"key":"3503_CR48","doi-asserted-by":"publisher","first-page":"1332781","DOI":"10.3389\/fimmu.2024.1332781","volume":"15","author":"C Perrone","year":"2024","unstructured":"Perrone C, et al. CD34(+)DNAM-1(bright)CXCR4(+) Haemopoietic precursors circulate after chemotherapy, seed lung tissue and generate functional innate-like T cells and NK cells. Front Immunol. 2024;15:1332781.","journal-title":"Front Immunol"},{"issue":"10","key":"3503_CR49","doi-asserted-by":"publisher","first-page":"e0139809","DOI":"10.1371\/journal.pone.0139809","volume":"10","author":"R Okita","year":"2015","unstructured":"Okita R, et al. Contrasting effects of the cytotoxic anticancer drug gemcitabine and the EGFR tyrosine kinase inhibitor gefitinib on NK Cell-Mediated cytotoxicity via regulation of NKG2D ligand in Non-Small-Cell lung cancer cells. PLoS ONE. 2015;10(10):e0139809.","journal-title":"PLoS ONE"},{"issue":"4","key":"3503_CR50","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1002\/cncr.23239","volume":"112","author":"P Carrega","year":"2008","unstructured":"Carrega P, et al. Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56 bright CD16(-) cells and display an impaired capability to kill tumor cells. Cancer. 2008;112(4):863\u201375.","journal-title":"Cancer"},{"issue":"10","key":"3503_CR51","doi-asserted-by":"publisher","first-page":"e109976","DOI":"10.1371\/journal.pone.0109976","volume":"9","author":"S Jin","year":"2014","unstructured":"Jin S, et al. NK cell phenotypic modulation in lung cancer environment. PLoS ONE. 2014;9(10):e109976.","journal-title":"PLoS ONE"},{"issue":"1","key":"3503_CR52","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/s41467-024-44789-z","volume":"15","author":"I Dean","year":"2024","unstructured":"Dean I, et al. Rapid functional impairment of natural killer cells following tumor entry limits anti-tumor immunity. Nat Commun. 2024;15(1):683.","journal-title":"Nat Commun"},{"issue":"1","key":"3503_CR53","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1158\/2159-8290.CD-20-0655","volume":"11","author":"B Cozar","year":"2021","unstructured":"Cozar B, et al. Tumor-Infiltrating natural killer cells. Cancer Discov. 2021;11(1):34\u201344.","journal-title":"Cancer Discov"},{"issue":"2","key":"3503_CR54","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41577-022-00732-1","volume":"23","author":"NK Wolf","year":"2023","unstructured":"Wolf NK, Kissiov DU, Raulet DH. Roles of natural killer cells in immunity to cancer, and applications to immunotherapy. Nat Rev Immunol. 2023;23(2):90\u2013105.","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"3503_CR55","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1007\/s00262-005-0669-2","volume":"54","author":"N Kundu","year":"2005","unstructured":"Kundu N, et al. Cyclooxygenase inhibitors modulate NK activities that control metastatic disease. Cancer Immunol Immunother. 2005;54(10):981\u20137.","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"3503_CR56","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1158\/0008-5472.CAN-17-2826","volume":"78","author":"A Young","year":"2018","unstructured":"Young A, et al. A2AR adenosine signaling suppresses natural killer cell maturation in the tumor microenvironment. Cancer Res. 2018;78(4):1003\u201316.","journal-title":"Cancer Res"},{"issue":"9","key":"3503_CR57","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1038\/ni.3809","volume":"18","author":"VS Cortez","year":"2017","unstructured":"Cortez VS, et al. SMAD4 impedes the conversion of NK cells into ILC1-like cells by curtailing non-canonical TGF-beta signaling. Nat Immunol. 2017;18(9):995\u20131003.","journal-title":"Nat Immunol"},{"issue":"9","key":"3503_CR58","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1038\/ni.3800","volume":"18","author":"Y Gao","year":"2017","unstructured":"Gao Y, et al. Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells. Nat Immunol. 2017;18(9):1004\u201315.","journal-title":"Nat Immunol"},{"issue":"1","key":"3503_CR59","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12865-021-00434-8","volume":"22","author":"YS Lee","year":"2021","unstructured":"Lee YS, et al. Downregulation of NKG2DLs by TGF-beta in human lung cancer cells. BMC Immunol. 2021;22(1):44.","journal-title":"BMC Immunol"},{"issue":"9","key":"3503_CR60","doi-asserted-by":"publisher","first-page":"3609","DOI":"10.1172\/JCI45816","volume":"121","author":"E Mamessier","year":"2011","unstructured":"Mamessier E, et al. Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J Clin Invest. 2011;121(9):3609\u201322.","journal-title":"J Clin Invest"},{"issue":"12","key":"3503_CR61","doi-asserted-by":"publisher","first-page":"7335","DOI":"10.4049\/jimmunol.172.12.7335","volume":"172","author":"JC Lee","year":"2004","unstructured":"Lee JC, et al. Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J Immunol. 2004;172(12):7335\u201340.","journal-title":"J Immunol"},{"issue":"12","key":"3503_CR62","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1038\/s41416-024-02677-9","volume":"130","author":"J Kment","year":"2024","unstructured":"Kment J, et al. Blockade of TGF-beta and PD-L1 by bintrafusp Alfa promotes survival in preclinical ovarian cancer models by promoting T effector and NK cell responses. Br J Cancer. 2024;130(12):2003\u201315.","journal-title":"Br J Cancer"},{"issue":"6","key":"3503_CR63","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1158\/1535-7163.MCT-20-0944","volume":"20","author":"N Ludwig","year":"2021","unstructured":"Ludwig N, et al. Novel TGFbeta inhibitors ameliorate oral squamous cell carcinoma progression and improve the antitumor immune response of Anti-PD-L1 immunotherapy. Mol Cancer Ther. 2021;20(6):1102\u201311.","journal-title":"Mol Cancer Ther"},{"issue":"14","key":"3503_CR64","doi-asserted-by":"publisher","first-page":"4400","DOI":"10.1158\/1078-0432.CCR-18-3183","volume":"25","author":"RA Burga","year":"2019","unstructured":"Burga RA, et al. Engineering the TGFbeta receptor to enhance the therapeutic potential of natural killer cells as an immunotherapy for neuroblastoma. Clin Cancer Res. 2019;25(14):4400\u201312.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"3503_CR65","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/s41590-025-02103-z","volume":"26","author":"A Rea","year":"2025","unstructured":"Rea A, et al. Enhancing human NK cell antitumor function by knocking out SMAD4 to counteract TGFbeta and activin A suppression. Nat Immunol. 2025;26(4):582\u201394.","journal-title":"Nat Immunol"},{"issue":"12","key":"3503_CR66","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1038\/s41590-019-0511-1","volume":"20","author":"X Zheng","year":"2019","unstructured":"Zheng X, et al. Mitochondrial fragmentation limits NK cell-based tumor immunosurveillance. Nat Immunol. 2019;20(12):1656\u201367.","journal-title":"Nat Immunol"},{"issue":"6","key":"3503_CR67","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/j.immuni.2020.05.001","volume":"52","author":"J Ni","year":"2020","unstructured":"Ni J, et al. Single-Cell RNA sequencing of Tumor-Infiltrating NK cells reveals that Inhibition of transcription factor HIF-1alpha unleashes NK cell activity. Immunity. 2020;52(6):1075\u2013e10878.","journal-title":"Immunity"},{"issue":"7","key":"3503_CR68","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1158\/2159-8290.CD-23-0426","volume":"14","author":"J Ye","year":"2024","unstructured":"Ye J, et al. Senescent CAFs mediate immunosuppression and drive breast cancer progression. Cancer Discov. 2024;14(7):1302\u201323.","journal-title":"Cancer Discov"},{"key":"3503_CR69","doi-asserted-by":"crossref","unstructured":"de Andrade LF et al. Discovery of specialized NK cell populations infiltrating human melanoma metastases. JCI Insight, 2019;4(23).","DOI":"10.1172\/jci.insight.133103"},{"issue":"1","key":"3503_CR70","doi-asserted-by":"publisher","first-page":"101277","DOI":"10.1016\/j.tranon.2021.101277","volume":"15","author":"EY Kim","year":"2022","unstructured":"Kim EY, et al. Early lung carcinogenesis and tumor microenvironment observed by single-cell transcriptome analysis. Transl Oncol. 2022;15(1):101277.","journal-title":"Transl Oncol"},{"issue":"34","key":"3503_CR71","doi-asserted-by":"publisher","first-page":"4029","DOI":"10.1200\/JCO.23.02747","volume":"42","author":"JC Yang","year":"2024","unstructured":"Yang JC, et al. Phase III KEYNOTE-789 study of pemetrexed and platinum with or without pembrolizumab for tyrosine kinase Inhibitor\u2013Resistant, EGFR-Mutant, metastatic nonsquamous Non-Small cell lung cancer. J Clin Oncol. 2024;42(34):4029\u201339.","journal-title":"J Clin Oncol"},{"issue":"1","key":"3503_CR72","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1038\/s41467-020-16164-1","volume":"11","author":"N Kim","year":"2020","unstructured":"Kim N, et al. Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma. Nat Commun. 2020;11(1):2285.","journal-title":"Nat Commun"},{"issue":"12","key":"3503_CR73","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1016\/j.ccell.2021.10.009","volume":"39","author":"AM Leader","year":"2021","unstructured":"Leader AM, et al. Single-cell analysis of human non-small cell lung cancer lesions refines tumor classification and patient stratification. Cancer Cell. 2021;39(12):1594\u2013e160912.","journal-title":"Cancer Cell"},{"issue":"1","key":"3503_CR74","doi-asserted-by":"publisher","first-page":"4388","DOI":"10.1038\/s41467-024-48700-8","volume":"15","author":"M De Zuani","year":"2024","unstructured":"De Zuani M, et al. Single-cell and Spatial transcriptomics analysis of non-small cell lung cancer. Nat Commun. 2024;15(1):4388.","journal-title":"Nat Commun"},{"key":"3503_CR75","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.3389\/fimmu.2018.01072","volume":"9","author":"H Georgiev","year":"2018","unstructured":"Georgiev H, et al. Coming of age: CD96 emerges as modulator of immune responses. Front Immunol. 2018;9:1072.","journal-title":"Front Immunol"},{"issue":"12","key":"3503_CR76","doi-asserted-by":"publisher","first-page":"e1515","DOI":"10.1002\/ctm2.1515","volume":"13","author":"C Chen","year":"2023","unstructured":"Chen C, et al. Single-cell and Spatial transcriptomics reveal POSTN(+) cancer-associated fibroblasts correlated with immune suppression and tumour progression in non-small cell lung cancer. Clin Transl Med. 2023;13(12):e1515.","journal-title":"Clin Transl Med"},{"issue":"5","key":"3503_CR77","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.21037\/jtd-21-1502","volume":"14","author":"BJ Knapp","year":"2022","unstructured":"Knapp BJ, Devarakonda S, Govindan R. Bone metastases in non-small cell lung cancer: a narrative review. J Thorac Dis. 2022;14(5):1696\u2013712.","journal-title":"J Thorac Dis"},{"issue":"12","key":"3503_CR78","doi-asserted-by":"publisher","first-page":"5191","DOI":"10.21037\/tcr-21-1507","volume":"10","author":"S Shi","year":"2021","unstructured":"Shi S, et al. Prediction of overall survival of non-small cell lung cancer with bone metastasis: an analysis of the surveillance, epidemiology and end results (SEER) database. Transl Cancer Res. 2021;10(12):5191\u2013203.","journal-title":"Transl Cancer Res"},{"key":"3503_CR79","doi-asserted-by":"publisher","first-page":"175883592412392","DOI":"10.1177\/17588359241239293","volume":"16","author":"J Gong","year":"2024","unstructured":"Gong J, et al. Bone metastasis in non-small-cell lung cancer: genomic characterization and exploration of potential targets. Ther Adv Med Oncol. 2024;16:17588359241239293.","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"3503_CR80","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1186\/s40425-019-0793-8","volume":"7","author":"L Landi","year":"2019","unstructured":"Landi L, et al. Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer. J Immunother Cancer. 2019;7(1):316.","journal-title":"J Immunother Cancer"},{"key":"3503_CR81","doi-asserted-by":"crossref","unstructured":"Sethakorn N et al. Advancing treatment of bone metastases through novel translational approaches targeting the bone microenvironment. Cancers (Basel), 2022;14(3).","DOI":"10.3390\/cancers14030757"},{"issue":"11","key":"3503_CR82","first-page":"2985","volume":"20","author":"MA Lopez-Olivo","year":"2012","unstructured":"Lopez-Olivo MA, et al. Bisphosphonates in the treatment of patients with lung cancer and metastatic bone disease: a systematic review and meta-analysis. Support Care Cancer. 2012;20(11):2985\u201398.","journal-title":"Support Care Cancer"},{"issue":"12","key":"3503_CR83","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1002\/jbmr.3618","volume":"33","author":"J Fornetti","year":"2018","unstructured":"Fornetti J, Welm AL, Stewart SA. Understanding the bone in cancer metastasis. J Bone Min Res. 2018;33(12):2099\u2013113.","journal-title":"J Bone Min Res"},{"issue":"1","key":"3503_CR84","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1200\/JCO.23.00753","volume":"42","author":"EF Gillespie","year":"2024","unstructured":"Gillespie EF, et al. Prophylactic radiation therapy versus standard of care for patients with High-Risk asymptomatic bone metastases: A multicenter, randomized phase II clinical trial. J Clin Oncol. 2024;42(1):38\u201346.","journal-title":"J Clin Oncol"},{"issue":"11","key":"3503_CR85","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1016\/j.ccell.2021.09.005","volume":"39","author":"Y Kfoury","year":"2021","unstructured":"Kfoury Y, et al. Human prostate cancer bone metastases have an actionable immunosuppressive microenvironment. Cancer Cell. 2021;39(11):1464\u2013e14788.","journal-title":"Cancer Cell"},{"key":"3503_CR86","doi-asserted-by":"publisher","first-page":"100069","DOI":"10.1016\/j.adcanc.2022.100069","volume":"6","author":"C Cohen","year":"2022","unstructured":"Cohen C, et al. CX3CL1 as potential immunotherapeutic tool for bone metastases in lung cancer: A preclinical study. Adv Cancer Biology - Metastasis. 2022;6:100069.","journal-title":"Adv Cancer Biology - Metastasis"},{"key":"3503_CR87","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-030-36667-4_1","volume":"1231","author":"MJ Conroy","year":"2020","unstructured":"Conroy MJ, Lysaght J. CX3CL1 signaling in the tumor microenvironment. Adv Exp Med Biol. 2020;1231:1\u201312.","journal-title":"Adv Exp Med Biol"},{"issue":"10","key":"3503_CR88","doi-asserted-by":"publisher","first-page":"4770","DOI":"10.7150\/thno.54235","volume":"11","author":"K Wang","year":"2021","unstructured":"Wang K, et al. Vertebral-specific activation of the CX3CL1\/ICAM-1 signaling network mediates non-small-cell lung cancer spinal metastasis by engaging tumor cell-vertebral bone marrow endothelial cell interactions. Theranostics. 2021;11(10):4770\u201389.","journal-title":"Theranostics"},{"issue":"7","key":"3503_CR89","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1002\/mc.23541","volume":"62","author":"XR Yang","year":"2023","unstructured":"Yang XR, et al. Heterogeneity in the immune microenvironment of bone metastasis in driver-positive non-small cell lung cancer. Mol Carcinog. 2023;62(7):1001\u20138.","journal-title":"Mol Carcinog"},{"issue":"8","key":"3503_CR90","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1038\/nm.2830","volume":"18","author":"BN Bidwell","year":"2012","unstructured":"Bidwell BN, et al. Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat Med. 2012;18(8):1224\u201331.","journal-title":"Nat Med"},{"issue":"11","key":"3503_CR91","doi-asserted-by":"publisher","first-page":"6658","DOI":"10.4049\/jimmunol.162.11.6658","volume":"162","author":"MJ Smyth","year":"1999","unstructured":"Smyth MJ, et al. Perforin is a major contributor to NK cell control of tumor metastasis. J Immunol. 1999;162(11):6658\u201362.","journal-title":"J Immunol"},{"key":"3503_CR92","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3389\/fimmu.2013.00012","volume":"4","author":"G Bernardini","year":"2013","unstructured":"Bernardini G, Sciume G, Santoni A. Differential chemotactic receptor requirements for NK cell subset trafficking into bone marrow. Front Immunol. 2013;4:12.","journal-title":"Front Immunol"},{"key":"3503_CR93","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.3389\/fimmu.2018.01829","volume":"9","author":"JE Melsen","year":"2018","unstructured":"Melsen JE, et al. Human bone Marrow-Resident natural killer cells have a unique transcriptional profile and resemble resident memory CD8(+) T cells. Front Immunol. 2018;9:1829.","journal-title":"Front Immunol"},{"key":"3503_CR94","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3389\/fendo.2019.00145","volume":"10","author":"I Roato","year":"2019","unstructured":"Roato I, Vitale M. The uncovered role of immune cells and NK cells in the regulation of bone metastasis. Front Endocrinol (Lausanne). 2019;10:145.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"10","key":"3503_CR95","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1002\/eji.201343448","volume":"43","author":"M Balsamo","year":"2013","unstructured":"Balsamo M, et al. Hypoxia downregulates the expression of activating receptors involved in NK-cell-mediated target cell killing without affecting ADCC. Eur J Immunol. 2013;43(10):2756\u201364.","journal-title":"Eur J Immunol"},{"key":"3503_CR96","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.3389\/fimmu.2018.02358","volume":"9","author":"M Parodi","year":"2018","unstructured":"Parodi M, et al. Hypoxia modifies the transcriptome of human NK cells, modulates their immunoregulatory profile, and influences NK cell subset migration. Front Immunol. 2018;9:2358.","journal-title":"Front Immunol"},{"key":"3503_CR97","doi-asserted-by":"crossref","unstructured":"Renema N et al. Rank-Rankl signalling in cancer. Biosci Rep, 2016.36(4).","DOI":"10.1042\/BSR20160150"},{"issue":"2","key":"3503_CR98","doi-asserted-by":"publisher","first-page":"821","DOI":"10.4049\/jimmunol.1201792","volume":"190","author":"BJ Schmiedel","year":"2013","unstructured":"Schmiedel BJ, et al. Receptor activator for NF-kappaB ligand in acute myeloid leukemia: expression, function, and modulation of NK cell immunosurveillance. J Immunol. 2013;190(2):821\u201331.","journal-title":"J Immunol"},{"key":"3503_CR99","doi-asserted-by":"crossref","unstructured":"Clar KL et al. Inhibition of NK reactivity against solid tumors by Platelet-Derived RANKL. Cancers (Basel), 2019;11(3).","DOI":"10.3390\/cancers11030277"},{"issue":"7","key":"3503_CR100","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1002\/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO;2-0","volume":"91","author":"JR Berenson","year":"2001","unstructured":"Berenson JR, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer. 2001;91(7):1191\u2013200.","journal-title":"Cancer"},{"issue":"9768","key":"3503_CR101","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","volume":"377","author":"K Fizazi","year":"2011","unstructured":"Fizazi K, et al. Denosumab versus Zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377(9768):813\u201322.","journal-title":"Lancet"},{"issue":"19","key":"3503_CR102","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","volume":"94","author":"F Saad","year":"2002","unstructured":"Saad F, et al. A randomized, placebo-controlled trial of Zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94(19):1458\u201368.","journal-title":"J Natl Cancer Inst"},{"key":"3503_CR103","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3389\/fimmu.2017.00297","volume":"8","author":"K Kaur","year":"2017","unstructured":"Kaur K, et al. Novel strategy to expand Super-Charged NK cells with significant potential to lyse and differentiate cancer stem cells: differences in NK expansion and function between healthy and cancer patients. Front Immunol. 2017;8:297.","journal-title":"Front Immunol"},{"issue":"5","key":"3503_CR104","doi-asserted-by":"publisher","first-page":"e1426518","DOI":"10.1080\/2162402X.2018.1426518","volume":"7","author":"K Kaur","year":"2018","unstructured":"Kaur K, et al. Super-charged NK cells inhibit growth and progression of stem-like\/poorly differentiated oral tumors in vivo in humanized BLT mice; effect on tumor differentiation and response to chemotherapeutic drugs. Oncoimmunology. 2018;7(5):e1426518.","journal-title":"Oncoimmunology"},{"issue":"29","key":"3503_CR105","doi-asserted-by":"publisher","first-page":"13028","DOI":"10.1073\/pnas.1000546107","volume":"107","author":"K Soderstrom","year":"2010","unstructured":"Soderstrom K, et al. Natural killer cells trigger osteoclastogenesis and bone destruction in arthritis. Proc Natl Acad Sci U S A. 2010;107(29):13028\u201333.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"3503_CR106","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1172\/JCI11176","volume":"106","author":"J Lam","year":"2000","unstructured":"Lam J, et al. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest. 2000;106(12):1481\u20138.","journal-title":"J Clin Invest"},{"issue":"24","key":"3503_CR107","doi-asserted-by":"publisher","first-page":"20002","DOI":"10.18632\/oncotarget.4755","volume":"6","author":"HC Tseng","year":"2015","unstructured":"Tseng HC, et al. Bisphosphonate-induced differential modulation of immune cell function in gingiva and bone marrow in vivo: role in osteoclast-mediated NK cell activation. Oncotarget. 2015;6(24):20002\u201325.","journal-title":"Oncotarget"},{"issue":"6812","key":"3503_CR108","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/35046102","volume":"408","author":"H Takayanagi","year":"2000","unstructured":"Takayanagi H, et al. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature. 2000;408(6812):600\u20135.","journal-title":"Nature"},{"issue":"3","key":"3503_CR109","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1111\/imm.12449","volume":"145","author":"S Feng","year":"2015","unstructured":"Feng S, et al. Interleukin-15-activated natural killer cells kill autologous osteoclasts via LFA-1, DNAM-1 and TRAIL, and inhibit osteoclast-mediated bone erosion in vitro. Immunology. 2015;145(3):367\u201379.","journal-title":"Immunology"},{"issue":"1","key":"3503_CR110","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41568-019-0220-y","volume":"20","author":"A Boire","year":"2020","unstructured":"Boire A, et al. Brain metastasis. Nat Rev Cancer. 2020;20(1):4\u201311.","journal-title":"Nat Rev Cancer"},{"key":"3503_CR111","doi-asserted-by":"crossref","unstructured":"Souza VGP et al. Advances Mol Landsc Lung Cancer Brain Metastasis Cancers (Basel), 2023;15(3).","DOI":"10.3390\/cancers15030722"},{"issue":"2","key":"3503_CR112","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1200\/JCO.2015.62.0138","volume":"34","author":"KL Johung","year":"2016","unstructured":"Johung KL, et al. Extended survival and prognostic factors for patients with ALK-Rearranged Non-Small-Cell lung cancer and brain metastasis. J Clin Oncol. 2016;34(2):123\u20139.","journal-title":"J Clin Oncol"},{"issue":"2","key":"3503_CR113","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/JTO.0000000000000069","volume":"9","author":"DY Shin","year":"2014","unstructured":"Shin DY, et al. EGFR mutation and brain metastasis in pulmonary adenocarcinomas. J Thorac Oncol. 2014;9(2):195\u20139.","journal-title":"J Thorac Oncol"},{"issue":"3","key":"3503_CR114","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.molmed.2021.12.008","volume":"28","author":"A Balatsoukas","year":"2022","unstructured":"Balatsoukas A, Rossignoli F, Shah K. NK cells in the brain: implications for brain tumor development and therapy. Trends Mol Med. 2022;28(3):194\u2013209.","journal-title":"Trends Mol Med"},{"issue":"5","key":"3503_CR115","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/imcb.12225","volume":"97","author":"F Ren","year":"2019","unstructured":"Ren F, et al. The R132H mutation in IDH1 promotes the recruitment of NK cells through CX3CL1\/CX3CR1 chemotaxis and is correlated with a better prognosis in gliomas. Immunol Cell Biol. 2019;97(5):457\u201369.","journal-title":"Immunol Cell Biol"},{"issue":"1","key":"3503_CR116","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13045-016-0272-3","volume":"9","author":"H Mostafa","year":"2016","unstructured":"Mostafa H, et al. Immune phenotypes predict survival in patients with glioblastoma multiforme. J Hematol Oncol. 2016;9(1):77.","journal-title":"J Hematol Oncol"},{"key":"3503_CR117","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/1755-8794-5-41","volume":"5","author":"E Vauleon","year":"2012","unstructured":"Vauleon E, et al. Immune genes are associated with human glioblastoma pathology and patient survival. BMC Med Genomics. 2012;5:41.","journal-title":"BMC Med Genomics"},{"issue":"1","key":"3503_CR118","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1186\/s12885-019-6324-7","volume":"19","author":"QY Zhong","year":"2019","unstructured":"Zhong QY, et al. A gene expression-based study on immune cell subtypes and glioma prognosis. BMC Cancer. 2019;19(1):1116.","journal-title":"BMC Cancer"},{"issue":"4","key":"3503_CR119","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.cell.2021.12.043","volume":"185","author":"H Gonzalez","year":"2022","unstructured":"Gonzalez H, et al. Cellular architecture of human brain metastases. Cell. 2022;185(4):729\u2013e74520.","journal-title":"Cell"},{"issue":"1","key":"3503_CR120","doi-asserted-by":"publisher","first-page":"5983","DOI":"10.1038\/s41467-022-33365-y","volume":"13","author":"Q Zhang","year":"2022","unstructured":"Zhang Q, et al. The Spatial transcriptomic landscape of non-small cell lung cancer brain metastasis. Nat Commun. 2022;13(1):5983.","journal-title":"Nat Commun"},{"issue":"4","key":"3503_CR121","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1038\/s41591-025-03530-z","volume":"31","author":"S Tagore","year":"2025","unstructured":"Tagore S, et al. Single-cell and Spatial genomic landscape of non-small cell lung cancer brain metastases. Nat Med. 2025;31(4):1351\u201363.","journal-title":"Nat Med"},{"key":"3503_CR122","doi-asserted-by":"publisher","first-page":"106132","DOI":"10.1016\/j.phrs.2022.106132","volume":"177","author":"X Fang","year":"2022","unstructured":"Fang X, et al. IDO1 can impair NK cells function against non-small cell lung cancer by downregulation of NKG2D ligand via ADAM10. Pharmacol Res. 2022;177:106132.","journal-title":"Pharmacol Res"},{"issue":"1","key":"3503_CR123","doi-asserted-by":"publisher","first-page":"2059874","DOI":"10.1080\/2162402X.2022.2059874","volume":"11","author":"M Li","year":"2022","unstructured":"Li M, et al. Immune suppressive microenvironment in brain metastatic non-small cell lung cancer: comprehensive immune microenvironment profiling of brain metastases versus paired primary lung tumors (GASTO 1060). Oncoimmunology. 2022;11(1):2059874.","journal-title":"Oncoimmunology"},{"key":"3503_CR124","doi-asserted-by":"crossref","unstructured":"Palano MT et al. Neutrophil and natural killer cell interactions in cancers: dangerous liaisons instructing immunosuppression and angiogenesis. Vaccines (Basel), 2021;9(12).","DOI":"10.3390\/vaccines9121488"},{"issue":"1","key":"3503_CR125","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41568-019-0224-7","volume":"20","author":"JH Sampson","year":"2020","unstructured":"Sampson JH, et al. Brain immunology and immunotherapy in brain tumours. Nat Rev Cancer. 2020;20(1):12\u201325.","journal-title":"Nat Rev Cancer"},{"key":"3503_CR126","doi-asserted-by":"publisher","first-page":"1221113","DOI":"10.3389\/fimmu.2023.1221113","volume":"14","author":"EM Brozos-Vazquez","year":"2023","unstructured":"Brozos-Vazquez EM, et al. Immunotherapy in patients with brain metastasis: advances and challenges for the treatment and the application of Circulating biomarkers. Front Immunol. 2023;14:1221113.","journal-title":"Front Immunol"},{"issue":"29","key":"3503_CR127","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.1200\/JCO.24.00553","volume":"42","author":"A Dowlati","year":"2024","unstructured":"Dowlati A, et al. Sustained clinical benefit and intracranial activity of Tarlatamab in previously treated small cell lung cancer: DeLLphi-300 trial update. J Clin Oncol. 2024;42(29):3392\u20139.","journal-title":"J Clin Oncol"},{"issue":"22","key":"3503_CR128","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","volume":"389","author":"MJ Ahn","year":"2023","unstructured":"Ahn MJ, et al. Tarlatamab for patients with previously treated Small-Cell lung cancer. N Engl J Med. 2023;389(22):2063\u201375.","journal-title":"N Engl J Med"},{"issue":"6852","key":"3503_CR129","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/35093109","volume":"413","author":"A Diefenbach","year":"2001","unstructured":"Diefenbach A, et al. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature. 2001;413(6852):165\u201371.","journal-title":"Nature"},{"issue":"6908","key":"3503_CR130","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1038\/nature01112","volume":"419","author":"V Groh","year":"2002","unstructured":"Groh V, et al. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature. 2002;419(6908):734\u20138.","journal-title":"Nature"},{"issue":"7143","key":"3503_CR131","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/nature05768","volume":"447","author":"BK Kaiser","year":"2007","unstructured":"Kaiser BK, et al. Disulphide-isomerase-enabled shedding of tumour-associated NKG2D ligands. Nature. 2007;447(7143):482\u20136.","journal-title":"Nature"},{"issue":"6383","key":"3503_CR132","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1126\/science.aao0505","volume":"359","author":"L de Ferrari","year":"2018","unstructured":"de Ferrari L, et al. Antibody-mediated Inhibition of MICA and MICB shedding promotes NK cell-driven tumor immunity. Science. 2018;359(6383):1537\u201342.","journal-title":"Science"},{"issue":"4","key":"3503_CR133","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.immuni.2008.02.016","volume":"28","author":"N Guerra","year":"2008","unstructured":"Guerra N, et al. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity. 2008;28(4):571\u201380.","journal-title":"Immunity"},{"issue":"10","key":"3503_CR134","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1038\/s41590-018-0209-9","volume":"19","author":"V Jelencic","year":"2018","unstructured":"Jelencic V, et al. NK cell receptor NKG2D sets activation threshold for the NCR1 receptor early in NK cell development. Nat Immunol. 2018;19(10):1083\u201392.","journal-title":"Nat Immunol"},{"key":"3503_CR135","doi-asserted-by":"publisher","first-page":"13930","DOI":"10.1038\/ncomms13930","volume":"8","author":"S Sheppard","year":"2017","unstructured":"Sheppard S, et al. The immunoreceptor NKG2D promotes tumour growth in a model of hepatocellular carcinoma. Nat Commun. 2017;8:13930.","journal-title":"Nat Commun"},{"key":"3503_CR136","doi-asserted-by":"publisher","unstructured":"Thompson TW et al. Endothelial cells express NKG2D ligands and desensitize antitumor NK responses. Elife, 2017;6.Dec 12:6:e30881. https:\/\/doi.org\/10.7554\/eLife.30881","DOI":"10.7554\/eLife.30881"},{"key":"3503_CR137","doi-asserted-by":"crossref","unstructured":"Curio S et al. NKG2D Fine-Tunes the local inflammatory response in colorectal cancer. Cancers (Basel), 2023;15(6).","DOI":"10.3390\/cancers15061792"},{"key":"3503_CR138","doi-asserted-by":"crossref","unstructured":"Serritella AV et al. The human soluble NKG2D ligand differentially impacts tumorigenicity and progression in Temporal and Model-Dependent modes. Biomedicines, 2024;12(1).","DOI":"10.3390\/biomedicines12010196"},{"issue":"1","key":"3503_CR139","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/s42003-021-02440-3","volume":"4","author":"P Dhar","year":"2021","unstructured":"Dhar P, et al. Tumor-derived NKG2D ligand sMIC reprograms NK cells to an inflammatory phenotype through CBM signalosome activation. Commun Biol. 2021;4(1):905.","journal-title":"Commun Biol"},{"issue":"10","key":"3503_CR140","doi-asserted-by":"publisher","first-page":"4410","DOI":"10.1172\/JCI69369","volume":"123","author":"G Liu","year":"2013","unstructured":"Liu G, et al. Perturbation of NK cell peripheral homeostasis accelerates prostate carcinoma metastasis. J Clin Invest. 2013;123(10):4410\u201322.","journal-title":"J Clin Invest"},{"issue":"1","key":"3503_CR141","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13045-020-00896-0","volume":"13","author":"F Basher","year":"2020","unstructured":"Basher F, et al. Antibody targeting tumor-derived soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival and function and enhances melanoma response to PDL1 Blockade therapy. J Hematol Oncol. 2020;13(1):74.","journal-title":"J Hematol Oncol"},{"issue":"21","key":"3503_CR142","doi-asserted-by":"publisher","first-page":"4819","DOI":"10.1158\/1078-0432.CCR-15-0845","volume":"21","author":"S Lu","year":"2015","unstructured":"Lu S, et al. Nonblocking monoclonal antibody targeting soluble MIC revamps endogenous innate and adaptive antitumor responses and eliminates primary and metastatic tumors. Clin Cancer Res. 2015;21(21):4819\u201330.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"3503_CR143","doi-asserted-by":"publisher","first-page":"e1602133","DOI":"10.1126\/sciadv.1602133","volume":"3","author":"J Zhang","year":"2017","unstructured":"Zhang J, et al. Antibody-mediated neutralization of soluble MIC significantly enhances CTLA4 Blockade therapy. Sci Adv. 2017;3(5):e1602133.","journal-title":"Sci Adv"},{"issue":"1","key":"3503_CR144","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/s40425-019-0693-y","volume":"7","author":"J Zhang","year":"2019","unstructured":"Zhang J, et al. Antibody targeting tumor-derived soluble NKG2D ligand sMIC provides dual co-stimulation of CD8 T cells and enables sMIC(+) tumors respond to PD1\/PD-L1 Blockade therapy. J Immunother Cancer. 2019;7(1):223.","journal-title":"J Immunother Cancer"},{"issue":"7","key":"3503_CR145","doi-asserted-by":"publisher","first-page":"e1323618","DOI":"10.1080\/2162402X.2017.1323618","volume":"6","author":"C Maccalli","year":"2017","unstructured":"Maccalli C, et al. Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint Blockade therapy of metastatic melanoma patients. Oncoimmunology. 2017;6(7):e1323618.","journal-title":"Oncoimmunology"},{"issue":"12","key":"3503_CR146","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1007\/s00262-006-0167-1","volume":"55","author":"S Holdenrieder","year":"2006","unstructured":"Holdenrieder S, et al. Soluble MICB in malignant diseases: analysis of diagnostic significance and correlation with soluble MICA. Cancer Immunol Immunother. 2006;55(12):1584\u20139.","journal-title":"Cancer Immunol Immunother"},{"issue":"8","key":"3503_CR147","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1111\/j.1349-7006.2012.02330.x","volume":"103","author":"K Yamaguchi","year":"2012","unstructured":"Yamaguchi K, et al. Diagnostic and prognostic impact of serum-soluble UL16-binding protein 2 in lung cancer patients. Cancer Sci. 2012;103(8):1405\u201313.","journal-title":"Cancer Sci"},{"key":"3503_CR148","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.coi.2015.12.007","volume":"39","author":"F Garrido","year":"2016","unstructured":"Garrido F, et al. The urgent need to recover MHC class I in cancers for effective immunotherapy. Curr Opin Immunol. 2016;39:44\u201351.","journal-title":"Curr Opin Immunol"},{"issue":"6024","key":"3503_CR149","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1126\/science.1203486","volume":"331","author":"RD Schreiber","year":"2011","unstructured":"Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity\u2019s roles in cancer suppression and promotion. Science. 2011;331(6024):1565\u201370.","journal-title":"Science"},{"issue":"11","key":"3503_CR150","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1038\/nbt.3344","volume":"33","author":"SA Shukla","year":"2015","unstructured":"Shukla SA, et al. Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes. Nat Biotechnol. 2015;33(11):1152\u20138.","journal-title":"Nat Biotechnol"},{"issue":"4","key":"3503_CR151","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ccell.2020.03.017","volume":"37","author":"AJ Schoenfeld","year":"2020","unstructured":"Schoenfeld AJ, Hellmann MD. Acquired resistance to immune checkpoint inhibitors. Cancer Cell. 2020;37(4):443\u201355.","journal-title":"Cancer Cell"},{"issue":"2","key":"3503_CR152","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.immuni.2006.06.013","volume":"25","author":"N Anfossi","year":"2006","unstructured":"Anfossi N, et al. Human NK cell education by inhibitory receptors for MHC class I. Immunity. 2006;25(2):331\u201342.","journal-title":"Immunity"},{"issue":"7051","key":"3503_CR153","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/nature03847","volume":"436","author":"S Kim","year":"2005","unstructured":"Kim S, et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature. 2005;436(7051):709\u201313.","journal-title":"Nature"},{"key":"3503_CR154","doi-asserted-by":"publisher","unstructured":"Piersma SJ et al. Expression of a single inhibitory member of the Ly49 receptor family is sufficient to license NK cells for effector functions. Elife, 2025;13.Mar 14:13:RP100218. https:\/\/doi.org\/10.7554\/eLife.100218.2","DOI":"10.7554\/eLife.100218.2"},{"issue":"10","key":"3503_CR155","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1084\/jem.20100986","volume":"207","author":"JM Elliott","year":"2010","unstructured":"Elliott JM, Wahle JA, Yokoyama WM. MHC class I-deficient natural killer cells acquire a licensed phenotype after transfer into an MHC class I-sufficient environment. J Exp Med. 2010;207(10):2073\u20139.","journal-title":"J Exp Med"},{"issue":"10","key":"3503_CR156","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1084\/jem.20100570","volume":"207","author":"NT Joncker","year":"2010","unstructured":"Joncker NT, et al. Mature natural killer cells reset their responsiveness when exposed to an altered MHC environment. J Exp Med. 2010;207(10):2065\u201372.","journal-title":"J Exp Med"},{"issue":"1","key":"3503_CR157","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1084\/jem.20181076","volume":"216","author":"MD Bern","year":"2019","unstructured":"Bern MD, et al. Inducible down-regulation of MHC class I results in natural killer cell tolerance. J Exp Med. 2019;216(1):99\u2013116.","journal-title":"J Exp Med"},{"issue":"6","key":"3503_CR158","doi-asserted-by":"publisher","first-page":"e81","DOI":"10.3324\/haematol.2013.103085","volume":"99","author":"N Korde","year":"2014","unstructured":"Korde N, et al. A phase II trial of pan-KIR2D Blockade with IPH2101 in smoldering multiple myeloma. Haematologica. 2014;99(6):e81\u20133.","journal-title":"Haematologica"},{"issue":"21","key":"3503_CR159","doi-asserted-by":"publisher","first-page":"5211","DOI":"10.1158\/1078-0432.CCR-16-1108","volume":"22","author":"M Carlsten","year":"2016","unstructured":"Carlsten M, et al. Checkpoint Inhibition of KIR2D with the monoclonal antibody IPH2101 induces contraction and hyporesponsiveness of NK cells in patients with myeloma. Clin Cancer Res. 2016;22(21):5211\u201322.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"3503_CR160","doi-asserted-by":"publisher","first-page":"4127","DOI":"10.4049\/jimmunol.1402447","volume":"197","author":"NT Shifrin","year":"2016","unstructured":"Shifrin NT, et al. Differential role of hematopoietic and nonhematopoietic cell types in the regulation of NK cell tolerance and responsiveness. J Immunol. 2016;197(10):4127\u201336.","journal-title":"J Immunol"},{"issue":"11","key":"3503_CR161","doi-asserted-by":"publisher","first-page":"4781","DOI":"10.1172\/JCI74337","volume":"124","author":"M Ardolino","year":"2014","unstructured":"Ardolino M, et al. Cytokine therapy reverses NK cell anergy in MHC-deficient tumors. J Clin Invest. 2014;124(11):4781\u201394.","journal-title":"J Clin Invest"},{"issue":"8","key":"3503_CR162","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1158\/2159-8290.CD-19-1409","volume":"10","author":"DY Torrejon","year":"2020","unstructured":"Torrejon DY, et al. Overcoming genetically based resistance mechanisms to PD-1 Blockade. Cancer Discov. 2020;10(8):1140\u201357.","journal-title":"Cancer Discov"},{"key":"3503_CR163","doi-asserted-by":"crossref","unstructured":"Nicolai CJ et al. NK cells mediate clearance of CD8(+) T cell-resistant tumors in response to STING agonists. Sci Immunol, 2020;5(45).","DOI":"10.1126\/sciimmunol.aaz2738"},{"key":"3503_CR164","doi-asserted-by":"publisher","first-page":"15776","DOI":"10.1038\/ncomms15776","volume":"8","author":"H Seo","year":"2017","unstructured":"Seo H, et al. IL-21-mediated reversal of NK cell exhaustion facilitates anti-tumour immunity in MHC class I-deficient tumours. Nat Commun. 2017;8:15776.","journal-title":"Nat Commun"},{"issue":"3","key":"3503_CR165","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41423-021-00634-7","volume":"18","author":"P Anderson","year":"2021","unstructured":"Anderson P, et al. HLA class I loss in colorectal cancer: implications for immune escape and immunotherapy. Cell Mol Immunol. 2021;18(3):556\u201365.","journal-title":"Cell Mol Immunol"},{"key":"3503_CR166","doi-asserted-by":"crossref","unstructured":"Piersma SJ et al. NK cell expansion requires HuR and mediates control of solid tumors and long-term virus infection. J Exp Med, 2023;220(11).","DOI":"10.1084\/jem.20231154"},{"key":"3503_CR167","doi-asserted-by":"publisher","first-page":"368","DOI":"10.3389\/fimmu.2015.00368","volume":"6","author":"W Wang","year":"2015","unstructured":"Wang W, et al. NK Cell-Mediated Antibody-Dependent cellular cytotoxicity in cancer immunotherapy. Front Immunol. 2015;6:368.","journal-title":"Front Immunol"},{"issue":"18","key":"3503_CR168","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1182\/blood-2012-04-425397","volume":"121","author":"R Romee","year":"2013","unstructured":"Romee R, et al. NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17). Blood. 2013;121(18):3599\u2013608.","journal-title":"Blood"},{"issue":"2","key":"3503_CR169","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/cac2.12394","volume":"43","author":"F Ghaedrahmati","year":"2023","unstructured":"Ghaedrahmati F, Esmaeil N, Abbaspour M. Targeting immune checkpoints: how to use natural killer cells for fighting against solid tumors. Cancer Commun (Lond). 2023;43(2):177\u2013213.","journal-title":"Cancer Commun (Lond)"},{"issue":"1","key":"3503_CR170","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s13287-022-02769-4","volume":"13","author":"PR Kennedy","year":"2022","unstructured":"Kennedy PR, Felices M, Miller JS. Challenges to the broad application of allogeneic natural killer cell immunotherapy of cancer. Stem Cell Res Ther. 2022;13(1):165.","journal-title":"Stem Cell Res Ther"},{"issue":"8","key":"3503_CR171","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1002\/eji.202048953","volume":"51","author":"O Demaria","year":"2021","unstructured":"Demaria O, et al. Natural killer cell engagers in cancer immunotherapy: next generation of immuno-oncology treatments. Eur J Immunol. 2021;51(8):1934\u201342.","journal-title":"Eur J Immunol"},{"issue":"9","key":"3503_CR172","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1158\/2326-6066.CIR-19-0837","volume":"8","author":"M Felices","year":"2020","unstructured":"Felices M, et al. Potent cytolytic activity and specific IL15 delivery in a Second-Generation trispecific killer engager. Cancer Immunol Res. 2020;8(9):1139\u201349.","journal-title":"Cancer Immunol Res"},{"issue":"7","key":"3503_CR173","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1016\/j.cell.2019.04.041","volume":"177","author":"L Gauthier","year":"2019","unstructured":"Gauthier L, et al. Multifunctional natural killer cell engagers targeting NKp46 trigger protective tumor immunity. Cell. 2019;177(7):1701\u2013e171316.","journal-title":"Cell"},{"issue":"34","key":"3503_CR174","doi-asserted-by":"publisher","first-page":"8646","DOI":"10.1200\/JCO.2005.02.4646","volume":"23","author":"B Burtness","year":"2005","unstructured":"Burtness B, et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic\/recurrent head and neck cancer: an Eastern cooperative oncology group study. J Clin Oncol. 2005;23(34):8646\u201354.","journal-title":"J Clin Oncol"},{"issue":"30","key":"3503_CR175","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.1200\/JCO.2018.78.3183","volume":"36","author":"S Qin","year":"2018","unstructured":"Qin S, et al. Efficacy and tolerability of First-Line cetuximab plus leucovorin, fluorouracil, and oxaliplatin (FOLFOX-4) versus FOLFOX-4 in patients with RAS Wild-Type metastatic colorectal cancer: the Open-Label, randomized, phase III TAILOR trial. J Clin Oncol. 2018;36(30):3031\u20139.","journal-title":"J Clin Oncol"},{"issue":"1","key":"3503_CR176","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","volume":"35","author":"A Passaro","year":"2024","unstructured":"Passaro A, et al. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. Ann Oncol. 2024;35(1):77\u201390.","journal-title":"Ann Oncol"},{"issue":"22","key":"3503_CR177","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1056\/NEJMoa2306441","volume":"389","author":"C Zhou","year":"2023","unstructured":"Zhou C, et al. Amivantamab plus chemotherapy in NSCLC with EGFR exon 20 insertions. N Engl J Med. 2023;389(22):2039\u201351.","journal-title":"N Engl J Med"},{"issue":"1","key":"3503_CR178","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13046-023-02918-4","volume":"43","author":"S Santana-Hernandez","year":"2024","unstructured":"Santana-Hernandez S, et al. NK cell-triggered CCL5\/IFNgamma-CXCL9\/10 axis underlies the clinical efficacy of neoadjuvant anti-HER2 antibodies in breast cancer. J Exp Clin Cancer Res. 2024;43(1):10.","journal-title":"J Exp Clin Cancer Res"},{"key":"3503_CR179","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.lungcan.2021.12.002","volume":"163","author":"A Desai","year":"2022","unstructured":"Desai A, et al. Antibody-drug conjugates: A promising novel therapeutic approach in lung cancer. Lung Cancer. 2022;163:96\u2013106.","journal-title":"Lung Cancer"},{"issue":"3","key":"3503_CR180","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1056\/NEJMoa2112431","volume":"386","author":"BT Li","year":"2022","unstructured":"Li BT, et al. Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell lung cancer. N Engl J Med. 2022;386(3):241\u201351.","journal-title":"N Engl J Med"},{"issue":"1","key":"3503_CR181","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JCO.23.02005","volume":"42","author":"F Meric-Bernstam","year":"2024","unstructured":"Meric-Bernstam F, et al. Efficacy and safety of trastuzumab Deruxtecan in patients with HER2-Expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol. 2024;42(1):47\u201358.","journal-title":"J Clin Oncol"},{"issue":"43","key":"3503_CR182","doi-asserted-by":"publisher","first-page":"3849","DOI":"10.18632\/oncotarget.27766","volume":"11","author":"TM Cardillo","year":"2020","unstructured":"Cardillo TM, et al. Predictive biomarkers for sacituzumab Govitecan efficacy in Trop-2-expressing triple-negative breast cancer. Oncotarget. 2020;11(43):3849\u201362.","journal-title":"Oncotarget"},{"key":"3503_CR183","doi-asserted-by":"publisher","first-page":"118","DOI":"10.3389\/fonc.2020.00118","volume":"10","author":"E Perrone","year":"2020","unstructured":"Perrone E, et al. Preclinical activity of sacituzumab govitecan, an Antibody-Drug conjugate targeting trophoblast Cell-Surface antigen 2 (Trop-2) linked to the active metabolite of Irinotecan (SN-38), in ovarian cancer. Front Oncol. 2020;10:118.","journal-title":"Front Oncol"},{"issue":"1","key":"3503_CR184","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ygyno.2011.03.002","volume":"122","author":"J Varughese","year":"2011","unstructured":"Varughese J, et al. High-grade, chemotherapy-resistant primary ovarian carcinoma cell lines overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody. Gynecol Oncol. 2011;122(1):171\u20137.","journal-title":"Gynecol Oncol"},{"issue":"6","key":"3503_CR185","doi-asserted-by":"publisher","first-page":"e5671","DOI":"10.1016\/j.ajog.2011.06.093","volume":"205","author":"J Varughese","year":"2011","unstructured":"Varughese J, et al. Cervical carcinomas overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody. Am J Obstet Gynecol. 2011;205(6):e5671\u20137.","journal-title":"Am J Obstet Gynecol"},{"issue":"16","key":"3503_CR186","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia A, et al. Sacituzumab Govitecan in metastatic Triple-Negative breast cancer. N Engl J Med. 2021;384(16):1529\u201341.","journal-title":"N Engl J Med"},{"issue":"6382","key":"3503_CR187","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint Blockade. Science. 2018;359(6382):1350\u20135.","journal-title":"Science"},{"issue":"10","key":"3503_CR188","doi-asserted-by":"publisher","first-page":"4654","DOI":"10.1172\/JCI99317","volume":"128","author":"J Hsu","year":"2018","unstructured":"Hsu J, et al. Contribution of NK cells to immunotherapy mediated by PD-1\/PD-L1 Blockade. J Clin Invest. 2018;128(10):4654\u201368.","journal-title":"J Clin Invest"},{"issue":"8","key":"3503_CR189","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1007\/s00262-020-02558-z","volume":"69","author":"MP Trefny","year":"2020","unstructured":"Trefny MP, et al. PD-1(+) natural killer cells in human non-small cell lung cancer can be activated by PD-1\/PD-L1 Blockade. Cancer Immunol Immunother. 2020;69(8):1505\u201317.","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"3503_CR190","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1172\/JCI133353","volume":"130","author":"SJ Judge","year":"2020","unstructured":"Judge SJ, et al. Minimal PD-1 expression in mouse and human NK cells under diverse conditions. J Clin Invest. 2020;130(6):3051\u201368.","journal-title":"J Clin Invest"},{"issue":"1","key":"3503_CR191","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.jaci.2020.04.044","volume":"147","author":"L Quatrini","year":"2021","unstructured":"Quatrini L, et al. Glucocorticoids and the cytokines IL-12, IL-15, and IL-18 present in the tumor microenvironment induce PD-1 expression on human natural killer cells. J Allergy Clin Immunol. 2021;147(1):349\u201360.","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"3503_CR192","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1038\/s41590-024-01884-z","volume":"25","author":"H Netskar","year":"2024","unstructured":"Netskar H, et al. Pan-cancer profiling of tumor-infiltrating natural killer cells through transcriptional reference mapping. Nat Immunol. 2024;25(8):1445\u201359.","journal-title":"Nat Immunol"},{"issue":"15","key":"3503_CR193","doi-asserted-by":"publisher","first-page":"eabj3286","DOI":"10.1126\/sciadv.abj3286","volume":"8","author":"MS Hasim","year":"2022","unstructured":"Hasim MS, et al. When killers become thieves: trogocytosed PD-1 inhibits NK cells in cancer. Sci Adv. 2022;8(15):eabj3286.","journal-title":"Sci Adv"},{"issue":"8000","key":"3503_CR194","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41586-023-06945-1","volume":"626","author":"E Vivier","year":"2024","unstructured":"Vivier E, et al. Natural killer cell therapies. Nature. 2024;626(8000):727\u201336.","journal-title":"Nature"},{"issue":"1","key":"3503_CR195","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","volume":"386","author":"HA Tawbi","year":"2022","unstructured":"Tawbi HA, et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med. 2022;386(1):24\u201334.","journal-title":"N Engl J Med"},{"issue":"9","key":"3503_CR196","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1038\/s41590-023-01569-z","volume":"24","author":"V Aggarwal","year":"2023","unstructured":"Aggarwal V, Workman CJ, Vignali DAA. LAG-3 as the third checkpoint inhibitor. Nat Immunol. 2023;24(9):1415\u201322.","journal-title":"Nat Immunol"},{"key":"3503_CR197","first-page":"167","volume":"11","author":"M Khan","year":"2020","unstructured":"Khan M, Arooj S, Wang H. NK Cell-Based Immune Checkp Inhib Front Immunol. 2020;11:167.","journal-title":"NK Cell-Based Immune Checkp Inhib Front Immunol"},{"issue":"7","key":"3503_CR198","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.cell.2018.10.014","volume":"175","author":"P Andre","year":"2018","unstructured":"Andre P, et al. Anti-NKG2A mAb is a checkpoint inhibitor that promotes Anti-tumor immunity by unleashing both T and NK cells. Cell. 2018;175(7):1731\u2013e174313.","journal-title":"Cell"},{"issue":"7","key":"3503_CR199","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1016\/j.cell.2018.10.028","volume":"175","author":"N van Montfoort","year":"2018","unstructured":"van Montfoort N, et al. NKG2A Blockade potentiates CD8 T cell immunity induced by cancer vaccines. Cell. 2018;175(7):1744\u2013e175515.","journal-title":"Cell"},{"issue":"29","key":"3503_CR200","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1080\/14796694.2024.2354160","volume":"20","author":"F Barlesi","year":"2024","unstructured":"Barlesi F, et al. PACIFIC-9: phase III trial of durvalumab\u2009+\u2009oleclumab or Monalizumab in unresectable stage III non-small-cell lung cancer. Future Oncol. 2024;20(29):2137\u201347.","journal-title":"Future Oncol"},{"issue":"11","key":"3503_CR201","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1158\/2159-8290.CD-23-0436","volume":"13","author":"T Cascone","year":"2023","unstructured":"Cascone T, et al. Neoadjuvant durvalumab alone or combined with novel Immuno-Oncology agents in resectable lung cancer: the phase II neocoast platform trial. Cancer Discov. 2023;13(11):2394\u2013411.","journal-title":"Cancer Discov"},{"issue":"29","key":"3503_CR202","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1200\/JCO.22.00227","volume":"40","author":"RS Herbst","year":"2022","unstructured":"Herbst RS, et al. An Open-Label, phase II, multidrug platform study of durvalumab alone or in combination with oleclumab or Monalizumab in patients with unresectable, stage III Non-Small-Cell lung cancer. J Clin Oncol. 2022;40(29):3383\u201393.","journal-title":"J Clin Oncol"},{"key":"3503_CR203","doi-asserted-by":"crossref","unstructured":"Patel SP et al. Phase 1\/2 study of Monalizumab plus durvalumab in patients with advanced solid tumors. J Immunother Cancer, 2024;12(2).","DOI":"10.1136\/jitc-2023-007340"},{"issue":"3","key":"3503_CR204","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1172\/JCI128895","volume":"130","author":"SY Neo","year":"2020","unstructured":"Neo SY, et al. CD73 immune checkpoint defines regulatory NK cells within the tumor microenvironment. J Clin Invest. 2020;130(3):1185\u201398.","journal-title":"J Clin Invest"},{"issue":"7","key":"3503_CR205","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1007\/s00262-023-03430-6","volume":"72","author":"J Bendell","year":"2023","unstructured":"Bendell J, et al. First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors. Cancer Immunol Immunother. 2023;72(7):2443\u201358.","journal-title":"Cancer Immunol Immunother"},{"key":"3503_CR206","first-page":"1","volume":"42","author":"EA Mittendorf","year":"2022","unstructured":"Mittendorf EA, et al. Neoadjuvant immunotherapy: leveraging the immune system to treat Early-Stage disease. Am Soc Clin Oncol Educ Book. 2022;42:1\u201315.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"3503_CR207","doi-asserted-by":"crossref","unstructured":"Tarhini AA et al. Neoadjuvant immunotherapy of locoregionally advanced solid tumors. J Immunother Cancer, 2022;10(8).","DOI":"10.1136\/jitc-2022-005036"},{"issue":"19","key":"3503_CR208","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1056\/NEJMoa2311926","volume":"390","author":"T Cascone","year":"2024","unstructured":"Cascone T, et al. Perioperative nivolumab in resectable lung cancer. N Engl J Med. 2024;390(19):1756\u201369.","journal-title":"N Engl J Med"},{"issue":"21","key":"3503_CR209","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","volume":"386","author":"PM Forde","year":"2022","unstructured":"Forde PM, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386(21):1973\u201385.","journal-title":"N Engl J Med"},{"issue":"18","key":"3503_CR210","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","volume":"389","author":"JV Heymach","year":"2023","unstructured":"Heymach JV, et al. Perioperative durvalumab for resectable Non-Small-Cell lung cancer. N Engl J Med. 2023;389(18):1672\u201384.","journal-title":"N Engl J Med"},{"issue":"6","key":"3503_CR211","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1056\/NEJMoa2302983","volume":"389","author":"H Wakelee","year":"2023","unstructured":"Wakelee H, et al. Perioperative pembrolizumab for Early-Stage Non-Small-Cell lung cancer. N Engl J Med. 2023;389(6):491\u2013503.","journal-title":"N Engl J Med"},{"key":"3503_CR212","doi-asserted-by":"publisher","unstructured":"Cascone T et al. Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial. Nat Med (2025)May 31 https:\/\/doi.org\/10.1038\/s41591-025-03746-z","DOI":"10.1038\/s41591-025-03746-z"},{"issue":"3","key":"3503_CR213","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41577-019-0224-6","volume":"20","author":"Y Wolf","year":"2020","unstructured":"Wolf Y, Anderson AC, Kuchroo VK. TIM3 comes of age as an inhibitory receptor. Nat Rev Immunol. 2020;20(3):173\u201385.","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"3503_CR214","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1158\/2326-6066.CIR-13-0171","volume":"2","author":"IP da Silva","year":"2014","unstructured":"da Silva IP, et al. Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 Blockade. Cancer Immunol Res. 2014;2(5):410\u201322.","journal-title":"Cancer Immunol Res"},{"issue":"6","key":"3503_CR215","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1158\/2326-6066.CIR-17-0708","volume":"6","author":"H Seo","year":"2018","unstructured":"Seo H, et al. IL21 therapy combined with PD-1 and Tim-3 Blockade provides enhanced NK cell antitumor activity against MHC class I-Deficient tumors. Cancer Immunol Res. 2018;6(6):685\u201395.","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"3503_CR216","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.immuni.2024.01.010","volume":"57","author":"N Joller","year":"2024","unstructured":"Joller N, Anderson AC, Kuchroo VK. LAG-3, TIM-3, and TIGIT: distinct functions in immune regulation. Immunity. 2024;57(2):206\u201322.","journal-title":"Immunity"},{"issue":"7","key":"3503_CR217","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/s41590-018-0132-0","volume":"19","author":"Q Zhang","year":"2018","unstructured":"Zhang Q, et al. Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity. Nat Immunol. 2018;19(7):723\u201332.","journal-title":"Nat Immunol"},{"issue":"11","key":"3503_CR218","doi-asserted-by":"publisher","first-page":"2703","DOI":"10.1016\/j.cell.2024.03.039","volume":"187","author":"Y Li","year":"2024","unstructured":"Li Y, et al. IGSF8 is an innate immune checkpoint and cancer immunotherapy target. Cell. 2024;187(11):2703\u2013e271623.","journal-title":"Cell"},{"issue":"5","key":"3503_CR219","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/S1470-2045(18)30148-7","volume":"19","author":"JM Wrangle","year":"2018","unstructured":"Wrangle JM, et al. ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2018;19(5):694\u2013704.","journal-title":"Lancet Oncol"},{"key":"3503_CR220","doi-asserted-by":"publisher","unstructured":"Wrangle JM et al. Lung-MAP S1800D: A phase II\/III study of N-803 (ALT-803) plus pembrolizumab versus standard of care in participants with stage IV or recurrent non-small cell lung cancer (NSCLC) previously treated with anti-PD-1 or anti-PD-L1 therapy. J Clin Oncol, 2024 (Volume 42, Number 16; abstr 2619) https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.2619","DOI":"10.1200\/JCO.2024.42.16_suppl.2619"},{"issue":"1","key":"3503_CR221","doi-asserted-by":"publisher","first-page":"EVIDoa2200167","DOI":"10.1056\/EVIDoa2200167","volume":"2","author":"K Chamie","year":"2023","unstructured":"Chamie K, et al. IL-15 superagonist NAI in BCG-Unresponsive Non-Muscle-Invasive bladder cancer. NEJM Evid. 2023;2(1):EVIDoa2200167.","journal-title":"NEJM Evid"},{"issue":"3","key":"3503_CR222","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.ccell.2020.12.014","volume":"39","author":"CM Gay","year":"2021","unstructured":"Gay CM, et al. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell. 2021;39(3):346\u2013e3607.","journal-title":"Cancer Cell"},{"issue":"10212","key":"3503_CR223","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","volume":"394","author":"L Paz-Ares","year":"2019","unstructured":"Paz-Ares L, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394(10212):1929\u201339.","journal-title":"Lancet"},{"issue":"5","key":"3503_CR224","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1084\/jem.161.5.1135","volume":"161","author":"A Doyle","year":"1985","unstructured":"Doyle A, et al. Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA in human small-cell lung cancer. J Exp Med. 1985;161(5):1135\u201351.","journal-title":"J Exp Med"},{"issue":"2","key":"3503_CR225","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.canlet.2009.03.005","volume":"282","author":"S Sodeur","year":"2009","unstructured":"Sodeur S, et al. Increased numbers of spontaneous SCLC metastasis in absence of NK cells after subcutaneous inoculation of different SCLC cell lines into pfp\/rag2 double knock out mice. Cancer Lett. 2009;282(2):146\u201351.","journal-title":"Cancer Lett"},{"key":"3503_CR226","doi-asserted-by":"publisher","unstructured":"Mamdani H et al. A phase II trial of Monalizumab in combination with durvalumab (MEDI4736) plus platinum-based chemotherapy for first-line treatment of extensive stage small cell lung cancer (MOZART): hoosier cancer research network LUN21-530 study. J Clin Oncol, 2024;Volume 42, Number 16_suppl https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.TPS8129","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS8129"},{"issue":"7971","key":"3503_CR227","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/s41586-023-06243-w","volume":"619","author":"DJ Baker","year":"2023","unstructured":"Baker DJ, et al. CAR T therapy beyond cancer: the evolution of a living drug. Nature. 2023;619(7971):707\u201315.","journal-title":"Nature"},{"issue":"8","key":"3503_CR228","first-page":"856","volume":"141","author":"MM Berrien-Elliott","year":"2023","unstructured":"Berrien-Elliott MM, Jacobs MT, Fehniger TA. Allogeneic Nat Killer Cell Therapy Blood. 2023;141(8):856\u201368.","journal-title":"Allogeneic Nat Killer Cell Therapy Blood"},{"issue":"10","key":"3503_CR229","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41568-022-00491-0","volume":"22","author":"TJ Laskowski","year":"2022","unstructured":"Laskowski TJ, Biederstadt A, Rezvani K. Natural killer cells in antitumour adoptive cell immunotherapy. Nat Rev Cancer. 2022;22(10):557\u201375.","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"3503_CR230","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1910607","volume":"382","author":"E Liu","year":"2020","unstructured":"Liu E, et al. Use of CAR-Transduced natural killer cells in CD19-Positive lymphoid tumors. N Engl J Med. 2020;382(6):545\u201353.","journal-title":"N Engl J Med"},{"issue":"1","key":"3503_CR231","doi-asserted-by":"publisher","first-page":"1825177","DOI":"10.1080\/2162402X.2020.1825177","volume":"9","author":"S Grote","year":"2020","unstructured":"Grote S, et al. Adapter chimeric antigen receptor (AdCAR)-engineered NK-92 cells: an off-the-shelf cellular therapeutic for universal tumor targeting. Oncoimmunology. 2020;9(1):1825177.","journal-title":"Oncoimmunology"},{"key":"3503_CR232","doi-asserted-by":"crossref","unstructured":"Grote S et al. Adapter chimeric antigen receptor (AdCAR)-Engineered NK-92 cells for the multiplex targeting of bone metastases. Cancers (Basel), 2021;13(5).","DOI":"10.3390\/cancers13051124"},{"issue":"3","key":"3503_CR233","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","volume":"30","author":"D Marin","year":"2024","unstructured":"Marin D, et al. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19(+) B cell tumors: a phase 1\/2 trial. Nat Med. 2024;30(3):772\u201384.","journal-title":"Nat Med"},{"key":"3503_CR234","doi-asserted-by":"crossref","unstructured":"Flieswasser T et al. Screening a broad range of solid and haematological tumour types for CD70 expression using a uniform IHC methodology as potential patient stratification method. Cancers (Basel), 2019;11(10).","DOI":"10.3390\/cancers11101611"},{"issue":"4","key":"3503_CR235","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/s41591-024-02826-w","volume":"30","author":"G Ghilardi","year":"2024","unstructured":"Ghilardi G, et al. T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy. Nat Med. 2024;30(4):984\u20139.","journal-title":"Nat Med"},{"key":"3503_CR236","doi-asserted-by":"publisher","first-page":"1074906","DOI":"10.3389\/fimmu.2022.1074906","volume":"13","author":"L Jia","year":"2022","unstructured":"Jia L, et al. Sintilimab plus autologous NK cells as second-line treatment for advanced non-small-cell lung cancer previous treated with platinum-containing chemotherapy. Front Immunol. 2022;13:1074906.","journal-title":"Front Immunol"},{"issue":"22","key":"3503_CR237","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, et al. Pembrolizumab plus chemotherapy in metastatic Non-Small-Cell lung cancer. N Engl J Med. 2018;378(22):2078\u201392.","journal-title":"N Engl J Med"},{"issue":"21","key":"3503_CR238","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","volume":"379","author":"L Paz-Ares","year":"2018","unstructured":"Paz-Ares L, et al. Pembrolizumab plus chemotherapy for squamous Non-Small-Cell lung cancer. N Engl J Med. 2018;379(21):2040\u201351.","journal-title":"N Engl J Med"},{"issue":"19","key":"3503_CR239","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, et al. Pembrolizumab versus chemotherapy for PD-L1-Positive Non-Small-Cell lung cancer. N Engl J Med. 2016;375(19):1823\u201333.","journal-title":"N Engl J Med"},{"issue":"8","key":"3503_CR240","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.cllc.2022.07.009","volume":"23","author":"L Zhou","year":"2022","unstructured":"Zhou L, et al. A phase IB trial of autologous Cytokine-Induced killer cells in combination with sintilimab, monoclonal antibody against programmed cell Death-1, plus chemotherapy in patients with advanced Non-Small-Cell lung cancer. Clin Lung Cancer. 2022;23(8):709\u201319.","journal-title":"Clin Lung Cancer"},{"issue":"20","key":"3503_CR241","doi-asserted-by":"publisher","first-page":"5368","DOI":"10.1158\/1078-0432.CCR-20-1141","volume":"26","author":"G Multhoff","year":"2020","unstructured":"Multhoff G, et al. Targeted natural killer Cell-Based adoptive immunotherapy for the treatment of patients with NSCLC after radiochemotherapy: A randomized phase II clinical trial. Clin Cancer Res. 2020;26(20):5368\u201379.","journal-title":"Clin Cancer Res"},{"issue":"20","key":"3503_CR242","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia SJ, et al. Durvalumab after chemoradiotherapy in stage III Non-Small-Cell lung cancer. N Engl J Med. 2017;377(20):1919\u201329.","journal-title":"N Engl J Med"},{"issue":"5","key":"3503_CR243","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1172\/JCI132712","volume":"130","author":"M Lin","year":"2020","unstructured":"Lin M, et al. Pembrolizumab plus allogeneic NK cells in advanced non-small cell lung cancer patients. J Clin Invest. 2020;130(5):2560\u20139.","journal-title":"J Clin Invest"},{"issue":"6","key":"3503_CR244","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1038\/s41591-025-03640-8","volume":"31","author":"Y Nieto","year":"2025","unstructured":"Nieto Y, et al. Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial. Nat Med. 2025;31(6):1987\u201393.","journal-title":"Nat Med"},{"key":"3503_CR245","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1146\/annurev-immunol-101921-044122","volume":"41","author":"O Kyrysyuk","year":"2023","unstructured":"Kyrysyuk O, Wucherpfennig KW. Designing cancer immunotherapies that engage T cells and NK cells. Annu Rev Immunol. 2023;41:17\u201338.","journal-title":"Annu Rev Immunol"},{"key":"3503_CR246","doi-asserted-by":"publisher","first-page":"621254","DOI":"10.3389\/fimmu.2020.621254","volume":"11","author":"EE Peterson","year":"2020","unstructured":"Peterson EE, Barry KC. The natural Killer-Dendritic cell immune axis in Anti-Cancer immunity and immunotherapy. Front Immunol. 2020;11:621254.","journal-title":"Front Immunol"},{"issue":"1","key":"3503_CR247","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/s42003-022-03402-z","volume":"5","author":"B Breznik","year":"2022","unstructured":"Breznik B, et al. Infiltrating natural killer cells bind, lyse and increase chemotherapy efficacy in glioblastoma stem-like tumorospheres. Commun Biol. 2022;5(1):436.","journal-title":"Commun Biol"},{"key":"3503_CR248","doi-asserted-by":"crossref","unstructured":"Kaur K et al. Probiotic-Treated Super-Charged NK cells efficiently clear poorly differentiated pancreatic tumors in Hu-BLT mice. Cancers (Basel), 2019;2(1).","DOI":"10.3390\/cancers12010063"},{"issue":"11","key":"3503_CR249","doi-asserted-by":"publisher","first-page":"eabk3327","DOI":"10.1126\/sciadv.abk3327","volume":"8","author":"MD Bunting","year":"2022","unstructured":"Bunting MD, et al. Extracellular matrix proteins regulate NK cell function in peripheral tissues. Sci Adv. 2022;8(11):eabk3327.","journal-title":"Sci Adv"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03503-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-025-03503-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03503-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T12:26:13Z","timestamp":1757420773000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-025-03503-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,23]]},"references-count":249,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3503"],"URL":"https:\/\/doi.org\/10.1186\/s13046-025-03503-7","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,23]]},"assertion":[{"value":"10 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"NS has served as an advisory board member for Amgen.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"251"}}